Lumos Pharma, an Austin, Texas-based early stage biopharmaceutical development company, raised $14m in Series A financing.
The round was co-led by Sante Ventures and New Enterprise Associates (NEA). As part of the Series A financing, Kevin Lalande, Managing Director, Sante Ventures, and Ed Mathers, Partner, NEA, will join Lumos’ Board of Directors.
Led by Founder, President, and CEO Rick Hawkins, and Chairman Jon Saxe, formerly of Hoffmann-LaRoche, Inc., Lumos Pharma develops LUM-001, a small molecule therapeutic for the rare disease Creatine Transporter Deficiency (CTD), an inborn error of metabolism.
In preclinical studies, the compound has shown disease modifying potential as a treatment for CTD.
It has also been granted orphan designation by the FDA.
The company will use the funds to support the preclinical and clinical development of LUM-001.
FinSMEs
05/02/2014